儿童炎症性肠病的精准治疗研究与应用

doi:10.12372/jcp.2025.24e0499

Abstract

Abstract:

Pediatric inflammatory bowel disease (IBD) is a chronic, recurrent inflammatory condition of the intestines with unknown etiology and complex pathogenesis, posing significant challenges in diagnosis and treatment. IBD severely impacts the growth and development of affected children, diminishes their quality of life, and may negatively influence their psychological and social behavior, imposing a substantial economic burden on society. In recent years, the incidence of pediatric IBD in China has been on the rise, drawing significant attention from pediatricians. Establishing a new model of precision therapy for pediatric IBD has become a goal for pediatricians and scholars worldwide. Precision medicine has proven effective in early screening and diagnosis of cancers and neonatal genetic diseases, providing new methods and perspectives for the treatment of pediatric IBD. This paper reviews the current application of precision therapy in pediatric IBD, elucidating its role in the treatment of pediatric IBD.

Key words: inflammatory bowel disease, precision therapy, treatment strategies, child

JIA Shuangzhen, KONG Yan, LIU Qian-chao, ZHU Ailin, WU Jie. Application of precision therapy in pediatric inflammatory bowel disease[J].Journal of Clinical Pediatrics, 2025, 43(3): 226-232.

References 47

[1]	El-Matary W, Carroll MW, Deslandres C, et al. The 2023 impact of inflammatory bowel disease in Canada: Special Populations-Children and Adolescents with IBD[J]. J Can Assoc Gastroenterol, 2023, 6(2): S35-S44.
[2]	Benchimol EI, Bernstein CN, Bitton A, et al. Trends in epidemiology of pediatric inflammatory bowel disease in Canada: distributed network analysis of multiple population-based provincial health administrative databases[J]. Am J Gastroenterol, 2017, 112(7): 1120-1134. doi: 10.1038/ajg.2017.97 pmid: 28417994
[3]	Fabián O, Kamaradová K. Morphology of inflammatory bowel diseases (IBD)[J]. Cesk Patol, 2022, 58(1): 27-37. pmid: 35387455
[4]	Berinstein JA, Aintabi D, Higgins PDR. In-hospital management of inflammatory bowel disease[J]. Curr Opin Gastroenterol, 2023, 39(4): 274-286.
[5]	Cho J, Kim S, Yang DH, et al. Mucosal immunity related to FOXP3+ regulatory T cells, Th17 cells and cytokines in pediatric inflammatory bowel disease[J]. J Korean Med Sci, 2018, 33(52): e336.
[6]	Yan JB, Luo MM, Chen ZY, et al. The function and role of the Th17/Treg cell balance in inflammatory bowel disease[J]. J Immunol Res, 2020: 8813558.
[7]	Gomez-Bris R, Saez A, Herrero-Fernandez B, et al. CD4 T-cell subsets and the pathophysiology of inflammatory bowel disease[J]. Int J Mol Sci, 2023, 24(3): 2696.
[8]	Gao H, Liu R, Huang H, et al. Susceptibility gene profiling elucidates the pathogenesis of inflammatory bowel disease and provides precision medicine[J]. Clin Transl Med, 2023, 13(9): e1404.
[9]	O'Brien CL, Summers KM, Martin NM, et al. The relationship between extreme inter-individual variation in macrophage gene expression and genetic susceptibility to inflammatory bowel disease[J]. Hum Genet, 2024, 143(3): 233-261.
[10]	White Z, Cabrera I, Kapustka I, et al. Microbiota as key factors in inflammatory bowel disease[J]. Front Microbiol, 2023, 14: 1155388.
[11]	Tani M, Shinzaki S, Asakura A, et al. Seasonal variations in gut microbiota and disease course in patients with inflammatory bowel disease[J]. PLoS One, 2023, 18(4): e0283880.
[12]	Yan J, Wang L, Gu Y, et al. Dietary patterns and gut microbiota changes in inflammatory bowel disease: current insights and future challenges[J]. Nutrients, 2022, 14(19): 4003.
[13]	McCoy J, Miller MR, Watson M, et al. Paediatric obesity and Crohn's disease: a descriptive review of disease phenotype and clinical course[J]. Paediatr Child Health, 2023, 29(3): 158-162.
[14]	Ghione S, Sarter H, Fumery M, et al. Dramatic increase in incidence of ulcerative colitis and Crohn's disease (1988-2011): a population-based study of french adolescents[J]. Am J Gastroenterol, 2018, 113(2): 265-272. doi: 10.1038/ajg.2017.228 pmid: 28809388
[15]	Wang XQ, Zhang Y, Xu CD, et al. Inflammatory bowel disease in Chinese children: a multicenter analysis over a decade from Shanghai[J]. Inflamm Bowel Dis, 2013, 19(2): 423-428.
[16]	Mao R, Chen M. Precision medicine in IBD: genes, drugs, bugs and omics[J]. Nat Rev Gastroenterol Hepatol, 2022, 19(2): 81-82.
[17]	Samuels A, Whaley KG, Minar P. Precision dosing of anti-TNF therapy in pediatric inflammatory bowel disease[J]. Curr Gastroenterol Rep, 2023, 25(11): 323-332. doi: 10.1007/s11894-023-00895-4 pmid: 37695555
[18]	Leung PY, Lui R, Chien MM. Asia-Pacific's first position papers on pediatric inflammatory bowel disease: Tackling unique challenges in the region[J]. J Gastroenterol Hepatol, 2023, 38(4): 481-482.
[19]	Bai BYH, Reppell M, Smaoui N, et al. Baseline expression of immune gene modules in blood is associated with primary response to anti-TNF therapy in Crohn's disease patients.[J]. J Crohns Colitis, 2024, 18(3):431-445.
[20]	van den Broek WWA, Ten Berg JM. Is a genotype-guided therapy the optimal strategy to personalize anti-thrombotic management in patients with acute coronary syndrome?[J]. Eur Heart J, 2022, 43: 4599-4600. doi: 10.1093/eurheartj/ehac219 pmid: 35678582
[21]	Shi X, Zhang Y, Zhang Y, et al. Personalized antiplatelet therapy based on CYP2C19 genotypes in Chinese ACS patients undergoing PCI: a randomized controlled trial[J]. Front Cardiovasc Med, 2021, 8: 676954.
[22]	Vuyyuru SK, Solitano V, Hogan M, et al. Efficacy and safety of IL-12/23 and IL-23 inhibitors for Crohn's disease: systematic review and meta-analysis[J]. Dig Dis Sci, 2023, 68(9): 3702-3713.
[23]	Wyatt NJ, Watson H, Anderson CA, et al. Defining predictors of responsiveness to advanced therapies in Crohn's disease and ulcerative colitis: protocol for the IBD-RESPONSE and nested CD-meta RESPONSE prospective, multicentre, observational cohort study in precision medicine[J]. BMJ Open, 2024, 14(4): e073639.
[24]	Neurath MF. Current and emerging therapeutic targets for IBD[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(5): 269-278. doi: 10.1038/nrgastro.2016.208 pmid: 28144028
[25]	Akhter N, Wilson A, Arefanian H, et al. Endoplasmic reticulum stress promotes the expression of TNF-α in THP-1 cells by mechanisms involving ROS/CHOP/HIF-1α and MAPK/NF-κB pathways[J]. Int J Mol Sci, 2023, 24(20): 15186.
[26]	Chen J, Xu F, Ruan X, et al. Therapeutic targets for inflammatory bowel disease: proteome-wide Mendelian randomization and colocalization analyses[J]. EBioMedicine, 2023, 89: 104494.
[27]	Lu H, Lin J, Xu C, et al. Cyclosporine modulates neutrophil functions via the SIRT6-HIF-1α-glycolysis axis to alleviate severe ulcerative colitis[J]. Clin Transl Med, 2021, 11(2): e334.
[28]	Viennois E, Baker MT, Xiao B, et al. Longitudinal study of circulating protein biomarkers in inflammatory bowel disease[J]. J Proteomics, 2015, 112: 166-179. doi: 10.1016/j.jprot.2014.09.002 pmid: 25230104
[29]	Glapa-Nowak A, Szczepanik M, Banaszkiewicz A, et al. C-reactive protein/albumin ratio at diagnosis of pediatric inflammatory bowel disease: a retrospective multi-center study[J]. Med Sci Monit, 2022, 28: e937842.
[30]	Essmann J, Keil C, Unruh O, et al. Fecal calprotectin is significantly linked to azathioprine metabolite concentrations in Crohn's disease[J]. Eur J Gastroenterol Hepatol, 2019, 31(1): 99-108.
[31]	Lee JY, Hall JA, Kroehling L, et al. Serum amyloid a proteins induce pathogenic Th17 cells and promote inflammatory disease[J]. Cell, 2020, 183(7): 2036-2039.
[32]	Mello JDC, Gomes LEM, Silva JF, et al. The role of chemokines and adipokines as biomarkers of Crohn's disease activity: a systematic review of the literature[J]. Am J Transl Res, 2021, 13(8): 8561-8574. pmid: 34539979
[33]	Polosukhina D, Singh K, Asim M, et al. CCL11 exacerbates colitis and inflammation-associated colon tumorigenesis[J]. Oncogene, 2021, 40(47): 6540-6546. doi: 10.1038/s41388-021-02046-3 pmid: 34625710
[34]	Kim Y, Park JH, Cho YR. Network-based approaches for disease-gene association prediction using protein-protein interaction networks[J]. Int J Mol Sci, 2022, 23(13): 7411.
[35]	Jha K, Saha S, Singh H. Prediction of protein-protein interaction using graph neural networks[J]. Sci Rep, 2022, 12(1): 8360.
[36]	Balogh OM, Benczik B, Horváth A, et al. Efficient link prediction in the protein-protein interaction network using topological information in a generative adversarial network machine learning model[J]. BMC Bioinformatics, 2022, 23(1): 78.
[37]	Wang X, Zhu H, Jiang Y, et al. PRODeepSyn: predicting anticancer synergistic drug combinations by embedding cell lines with protein-protein interaction network[J]. Brief Bioinform, 2022, 23(2): bbab587.
[38]	Yuan Q, Chen J, Zhao H, et al. Structure-aware protein-protein interaction site prediction using deep graph convolutional network[J]. Bioinformatics, 2021, 38(1): 125-132. doi: 10.1093/bioinformatics/btab643 pmid: 34498061
[39]	Fiocchi C, Dragoni G, Iliopoulos D, et al. Results of the seventh scientific workshop of ECCO: precision medicine in IBD-What, Why, and How[J]. J Crohns Colitis, 2021, 15(9): 1410-1430.
[40]	LeVatte M, Keshteli AH, Zarei P, et al. Applications of metabolomics to precision nutrition[J]. Lifestyle Genom, 2022, 15(1): 1-9.
[41]	Hart L, Verburgt CM, Wine E, et al. Nutritional therapies and their influence on the intestinal microbiome in pediatric inflammatory bowel disease[J]. Nutrients, 2021, 14(1): 4.
[42]	Kasapoglu M, Yadavalli R, Nawaz S, et al. The impact of microbiome interventions on the progression and severity of inflammatory bowel disease: a systematic review[J]. Cureus, 2024, 16(5): e60786.
[43]	Höyhtyä M, Korpela K, Saqib S, et al. Quantitative fecal microbiota profiles relate to therapy response during induction with tumor necrosis factor α antagonist infliximab in pediatric inflammatory bowel disease[J]. Inflamm Bowel Dis, 2023, 29(1): 116-124.
[44]	Sitkin S, Pokrotnieks J. Targeted probiotics against bacterial-fungal biofilms: a new concept seems to bring us closer to microbiome-modulating therapy for inflammatory bowel disease[J]. Inflamm Bowel Dis, 2023, 29(11): e40-e41.
[45]	Al Radi ZMA, Prins FM, Collij V, et al. Exploring the predictive value of gut microbiome signatures for therapy intensification in patients with inflammatory bowel disease: a 10-year follow-up study[J]. Inflamm Bowel Dis, 2024: izae064.
[46]	Syed S, Boland BS, Bourke LT, et al. Challenges in IBD research 2024: precision medicine[J]. Inflamm Bowel Dis, 2024, 30(2): S39-S54.
[47]	Dart RJ, Ellul P, Scharl M, et al. Results of the seventh scientific workshop of ECCO: Precision Medicine in IBD - Challenges and Future Directions[J]. J Crohns Colitis, 2021, 15(9): 1407-1409. doi: 10.1093/ecco-jcc/jjab049 pmid: 33783484

Application of precision therapy in pediatric inflammatory bowel disease

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References 47

Related Articles 15

Metrics

Comments

Recommended 0

[1]	LIN Jinfeng, CHEN Yi, DENG Yan, FENG Ai, HUANG Juan, CHEN Lizhu, XIE Jingqi, NIE Xiaojing. A comparative study on the detection of anti-Nephrin antibodies in children's nephrotic syndrome by chemiluminescence method and cell-based assay [J]. Journal of Clinical Pediatrics, 2026, 44(8): 682-689.
[2]	ZHENG Fangyuan, WANG Miao, DING Mingming, LU Aidong, JIA Yueping, ZENG Huimin, ZHANG Leping. Next-generation sequencing identified gene variants and their prognostic impact in pediatric Philadelphia chromosome positive acute lymphoblastic leukemia [J]. Journal of Clinical Pediatrics, 2026, 44(8): 690-697.
[3]	ZHANG Xiao, FANG Hongjun, KUANG Xiaojun, WANG Lijuan, WU Zhao, JIANG Sha, LI Pei, WU Liwen. Analysis of the clinical and electrophysiological characteristics of atonic seizures in children [J]. Journal of Clinical Pediatrics, 2026, 44(8): 698-704.
[4]	WANG Mengqian, YANG Hui. Case series analysis of 13 intestinal Behcet’s syndrome in children [J]. Journal of Clinical Pediatrics, 2026, 44(8): 705-711.
[5]	WU Xirong, GAO Qi, GUO Siyuan, YIN Qingqin, QIN Qiang, YIN Ju, JIAO Anxia, CHEN Chenghao, WU Di, WANG Bei, DUAN Xiaomin, PENG Yun, XU Baoping, GAO Liwei. Clinical characteristics and prognosis of pulmonary mucormycosis in children with diabetes mellitus [J]. Journal of Clinical Pediatrics, 2026, 44(8): 712-720.
[6]	HAN Yanan, GE Lanlan, CUI Jieyuan. A case report of branchio-oto-renal syndrome caused by EYA1 gene variant with a 6-year follow-up [J]. Journal of Clinical Pediatrics, 2026, 44(8): 721-726.
[7]	SHI Jiayi, GAO Chunlin, JIA Lili, LU Yunyun, SUN Tao, ZHU Xiaodong, XIA Zhengkun, ZHANG Pei. Phenotypic characteristics and prognostic analysis of a pedigree with childhood isolated nephrotic syndrome caused by compound heterozygous mutations in the COQ2 gene [J]. Journal of Clinical Pediatrics, 2026, 44(8): 727-732.
[8]	Rachel Rosen, Osvaldo Borrelli, Christophe Faure, Katja Karrento, Usha Krishnan, Samuel Nurko, Nathalie Rommel, Alan Silverman, Michiel van Wijk, Marc Benninga (Author), Chinese Medical Association Parenteral and Enteral Nutrition Branch Pediatrics Group, The Subspecialty Group of Gastroenterology, The Society of Pediatric, Chinese Medical Association, Gastroenterology Group, Pediatrician Branch, Chinese Medical Doctor Association (Translator). Core interpretation and explanation of Rome Ⅴ diagnostic criteria: upper gastrointestinal disorders of gut-brain interaction in children and adolescents [J]. Journal of Clinical Pediatrics, 2026, 44(7): 595-608.
[9]	Carlo Di Lorenzo, Miguel Saps, Bruno P. Chumpitazi, Shaman Rajindrajith, Annamaria Staiano, Nikhil Thapar, Miranda van Tilburg, Carlos Velasco-Benítez, Arine Vlieger (Author), Chinese Medical Association Parenteral and Enteral Nutrition Branch Pediatrics Group, The Subspecialty Group of Gastroenterology, The Society of Pediatric, Chinese Medical Association, Gastroenterology Group, Pediatrician Branch, Chinese Medical Doctor Association (Translator). Core interpretation and explanation of Rome Ⅴ diagnostic criteria: lower and biliary disorders of gut-brain interaction in children and adolescents [J]. Journal of Clinical Pediatrics, 2026, 44(7): 609-621.
[10]	LI Xufeng, TANG Haoxun, LI Xingjun, ZHANG Lize, GAO Chenqing, ZHAO Shunying, LIU Jianhua. Clinical characteristics, chest CT imaging phenotypes, and their correlation with prognosis in 76 children with Chlamydia pneumoniae pneumonia [J]. Journal of Clinical Pediatrics, 2026, 44(7): 622-627.
[11]	WANG Zhen, SHAO Jingbo, ZHANG Na, XIA Min, ZHU Jiashi, DU Chengkan, LI Hong. Factors influencing long-term recurrence in pediatric acute lymphoblastic leukemia patients with low-risk disease at initial diagnosis: a five-year follow-up analysis of 254 cases from a single center [J]. Journal of Clinical Pediatrics, 2026, 44(7): 628-635.
[12]	GUO Xuemei, XUE Yao, WANG Yongren, RONG Liucheng, FANG Yongjun, LIN Rufeng. Clinical features and prognosis of childhood acute myeloid leukemia with CBFA2T3::GLIS2 fusion [J]. Journal of Clinical Pediatrics, 2026, 44(7): 636-643.
[13]	YANG Lijun, FU Dongxia, CUI Yan, YANG Junmei, ZHANG Liming. Clinical manifestation and genetic analysis of CHARGE syndrome caused by CHD7 gene variation [J]. Journal of Clinical Pediatrics, 2026, 44(7): 644-650.
[14]	HU Yan, YANG Fan, LIANG Aimin, MAO Meng. Identification and management of faltering growth in children: insights from the 13th International Conference on Nutrition and Growth [J]. Journal of Clinical Pediatrics, 2026, 44(6): 485-488.
[15]	LIU Ziyao, WANG Congying, WANG Hongmao, ZHANG Mingming, XU Yingjie, LAI Jianming, NIU Wenquan, LI Xiaohui. Early differentiation of Kawasaki disease with joint symptoms and systemic juvenile idiopathic arthritis with Kawasaki disease-like symptoms: a single-center retrospective study [J]. Journal of Clinical Pediatrics, 2026, 44(6): 489-498.